# ANTI-SARS-CoV-2 SEROCONVERSIO IN IMMUNE-MEDIATED KIDNEY DISEASES

> **NCT06753942** · — · COMPLETED · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 120 (actual)

## Conditions studied

- Immune-mediated Diseases
- Glomerulonephritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06753942
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-09
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06753942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06753942, "ANTI-SARS-CoV-2 SEROCONVERSIO IN IMMUNE-MEDIATED KIDNEY DISEASES". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06753942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*